Literature DB >> 369014

Expanded microporous polytetrafluoroethylene as a vascular substitute: a two year follow-up.

C D Campbell, D H Brooks, M W Webster, D L Diamond, R L Peel, H T Bahnson.   

Abstract

Since 1974, 131 femoropopliteal, distal popliteal, and tibial bypasses have been performed using expanded microporous polytetrafluoroethylene (PTFE). Forty patients were operated on for limb salvage, and 21 had had previous bypass procedures. The overall patency rate was 82%. Early occlusions possibly were related to technical error, but most probably were due to severity of disease and poor runoff. Late occlusions were related to progressive atherosclerosis in the proximal or distal arterial tree. A 75.7% cumulative patency rate was noted at 28 months. In man the PTFE prosthesis demonstrates a smooth intimal lining with fibroblastic ingrowth into the interstices of the graft. These results are considered to be excellent in this high-risk patient population. The patency rates achieved with PTFE are better than those accomplished with alternative conduits and approach the patency rates reported with autogenous saphenous vein. Expanded microporous polytetrafluoroethylene with its high patency, pliability, and tissue incorporation is an excellent arterial substitute. Only with continued use of this material and a more uniform patient selection can more equitable comparisons be made between expanded PTFE and the autogenous vein.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 369014

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  2 in total

1.  Proliferation of endothelial cell on polytetrafluoroethylene vascular graft materials carried VEGF gene plasmid.

Authors:  Si-feng Tao; Li Chen; Yi-xiong Zheng; Yuan Xu; Jian Chen; Hong Yu
Journal:  J Zhejiang Univ Sci B       Date:  2006-06       Impact factor: 3.066

2.  Seven-year follow-up of expanded polytetrafluoroethylene (PTFE) femoropopliteal bypass grafts.

Authors:  C E McAuley; D L Steed; M W Webster
Journal:  Ann Surg       Date:  1984-01       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.